Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $226,989 | $216,111 | $243,066 | $304,282 |
| - Cash | $66,396 | $70,605 | $84,225 | $103,756 |
| + Debt | $30,995 | $39,893 | $42,251 | $44,251 |
| Enterprise Value | $191,588 | $185,399 | $201,092 | $244,777 |
| Revenue | $12,621 | $61,641 | $49,639 | $12,112 |
| % Growth | -79.5% | 24.2% | 309.8% | – |
| Gross Profit | $12,621 | $5,619 | $6,011 | -$22,301 |
| % Margin | 100% | 9.1% | 12.1% | -184.1% |
| EBITDA | -$46,911 | -$7,578 | -$12,279 | -$43,229 |
| % Margin | -371.7% | -12.3% | -24.7% | -356.9% |
| Net Income | -$49,471 | -$7,570 | -$58,103 | -$52,809 |
| % Margin | -392% | -12.3% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| Operating Cash Flow | -$6,896 | -$32,558 | -$19,154 | -$58,457 |
| Capital Expenditures | -$391 | -$2,351 | -$1,122 | -$1,330 |
| Free Cash Flow | -$7,287 | -$34,909 | -$20,276 | -$59,787 |